Mode
Text Size
Log in / Sign up
N/A Completed N=30 Treatment

FLAIR™ Delivery System Study

Constriction, Pathologic
Source: ClinicalTrials.gov NCT00614315 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Oct 2010
Primary outcomePrimary: Technical Success for Delivery — 100 Percentage of successful implantations

Summary

The objective of this clinical study is to evaluate the performance of the Optimized FLAIR™ Delivery System.

Outcome Measures

OutcomeResultp-value
PRIMARY
Technical Success for Delivery
100 —
SECONDARY
Number of Device/Procedure-related Adverse Events(Safety of Delivery)
1 —

Eligibility Criteria

Inclusion Criteria

  • The subject is either a male or non-pregnant female ≥ 18 years old.
  • The subject has been properly informed about the study per IRB requirements, and has signed and dated the IRB-approved ICF.
  • The subject is willing to comply with the protocol requirements and can be contacted by telephone.
  • The subject has a synthetic AV access graft located in an arm that has been implanted for > 30 days and has undergone at least one successful dialysis session prior to the index procedure.
  • Angiographic evidence indicates that the subject has a stenosis of >50% located at the graft-vein anastomosis of the subject's synthetic AV access graft.
  • The target lesion is estimated to be ≤ 7 cm in length by angiography prior to performance of any interventional procedures.
  • The entire target lesion is located within 7 cm of the graft-vein anastomosis, as verified by angiography, such that approximately 1 cm of the FLAIR™ Endovascular Stent Graft will extend into non-diseased vein and approximately 1 cm but no more than 2 cm of the FLAIR™ Endovascular Stent Graft will extend into non-diseased AV graft.
  • Graft diameter at the deployment site is between 5 mm and 8 mm, as verified by angiography.
  • Full expansion of an appropriately sized angioplasty balloon, in the operator's judgment, can be achieved during primary angioplasty.

Exclusion Criteria

  • The subject has a life expectancy of 90 degrees.
  • The subject has an uncorrected blood coagulation disorder.
  • The subject has a known allergy or sensitivity to contrast media which cannot be adequately pre-medicated.
  • Subject is currently enrolled or scheduled to be enrolled in other investigations that conflict with follow-up testing or confounds data in this trial.
  • The subject has a known hypersensitivity to nickel-titanium.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00614315). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search